MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Ozempic could help with his as a study by Goldman Sachs found that the mass-adoption of GLP-1 series drugs could allow for ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

A new systematic review found that eating unprocessed red meat didn’t significantly impact body weight or metabolic health.

Costa Rica is facing a growing obesity crisis, with two-thirds of adults overweight or obese. A longtime expat reflects on ...

MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

A collection of videos, study abstracts, and other resources all focused on disparities in obesity. Obesity is independently ...

Ecnoglutide is a novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist shown to cause sustained weight loss.

The global prevalence of OA attributed to high BMI has steadily increased over the past 3 decades, particularly among women and in high-SDI regions.